Overview

A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency

Status:
Terminated

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Phase:

Phase 3

Details

Lead Sponsor:

Opko Biologics
OPKO Health, Inc.

Treatments:

Hormones